Shots:

• Athena Biosciences announced that the US FDA has approved Qdolo (tramadol hydrochloride) oral solution 5mg/1mL C-IV
• The most common AE’s (≥15.0%) observed in patients were dizziness/vertigo- nausea- constipation- headache- somnolence- vomiting- and pruritus
• Qdolo is indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. It will be available at chain- independent- and specialty pharmacies
  
    | Ref: PRNewswire  | Image: Pharma Compass